Browse by Journal Title

Article

Occurrence and risk factors of relapse activity after vaccination against COVID-19 in people with multiple sclerosis: 1-year follow-up results from a nationwide longitudinal observational study.
Fneish, F., Frahm, N., Peters, M., Ellenberger, D., Haas, J., Löbermann, M., Pöhlau, D., Röper, A.L., Schilling, S., Stahmann, A., Temmes, H., Paul, F. and Zettl, U.K.
Vaccines 11 (12): 1859. 16 December 2023

Stepwise conformational stabilization of a HIV-1 Clade C consensus envelope trimer immunogen impacts the profile of vaccine-induced antibody responses.
Hauser, A., Carnell, G., Held, K., Sulbaran, G., Tischbierek, N., Rogers, L., Pollakis, G., Tonks, P., Hoelscher, M., Ding, S., Sanders, R.W., Geldmacher, C., Sattentau, Q., Weissenhorn, W., Heeney, J.L., Peterhoff, D. and Wagner, R.
Vaccines 9 (7): 750. 6 July 2021

Augmenting the immune response against a stabilized HIV-1 Clade C envelope trimer by silica nanoparticle delivery.
Peterhoff, D., Thalhauser, S., Sobczak, J.M., Mohsen, M.O., Voigt, C., Seifert, N., Neckermann, P., Hauser, A., Ding, S., Sattentau, Q., Bachmann, M.F., Breunig, M. and Wagner, R.
Vaccines 9 (6): 642. 11 June 2021

Review

Envelope glycoprotein trimers as HIV-1 vaccine immunogens.
Sattentau, Q.J.
Vaccines 1 (4): 497-512. 28 October 2013